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Abstract
As the pentaspan stem cell marker CD133 was shown to bind cholesterol and to localize in plasma membrane protrusions,
we investigated a possible function for CD133 in endocytosis. Using the CD133 siRNA knockdown strategy and non-
differentiated human colon cancer Caco-2 cells that constitutively over-expressed CD133, we provide for the first time direct
evidence for a role of CD133 in the intracellular accumulation of fluorescently labeled extracellular compounds. Assessed
using AC133 monoclonal antibody, CD133 knockdown was shown to improve Alexa488-transferrin (Tf) uptake in Caco-2
cells but had no impact on FITC-dextran or FITC-cholera-toxin. Absence of effect of the CD133 knockdown on Tf recycling
established a role for CD133 in inhibiting Tf endocytosis rather than in stimulating Tf exocytosis. Use of previously identified
inhibitors of known endocytic pathways and the positive impact of CD133 knockdown on cellular uptake of clathrin-
endocytosed synthetic lipid nanocapsules supported that CD133 impact on endocytosis was primarily ascribed to the
clathrin pathway. Also, cholesterol extraction with methyl-b-cyclodextrine up regulated Tf uptake at greater intensity in the
CD133
high situation than in the CD133
low situation, thus suggesting a role for cholesterol in the inhibitory effect of CD133 on
endocytosis. Interestingly, cell treatment with the AC133 antibody down regulated Tf uptake, thus demonstrating that
direct extracellular binding to CD133 could affect endocytosis. Moreover, flow cytometry and confocal microscopy
established that down regulation of CD133 improved the accessibility to the TfR from the extracellular space, providing a
mechanism by which CD133 inhibited Tf uptake. As Tf is involved in supplying iron to the cell, effects of iron
supplementation and deprivation on CD133/AC133 expression were investigated. Both demonstrated a dose-dependent
down regulation here discussed to the light of transcriptional and post-transciptional effects. Taken together, these data
extend our knowledge of the function of CD133 and underline the interest of further exploring the CD133-Tf-iron network.
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Introduction
Following the use of new monoclonal antibodies raised against
neuroepithelial and hematopoietic stem cells, CD133, also known
in humans and rodents as Prominin-1, was first isolated and cloned
in 1997 [1,2,3]. CD133 is a five-domain transmembrane protein,
composed of an N-terminal extracellular tail, two small cytoplas-
mic loops, two large extracellular loops containing seven potential
glycosylation sites and a short C-terminal intracellular tail that can
be alternatively spliced [4] or phosphorylated [5].
Despite constant research efforts, the biological function of
CD133 remains largely unknown. Among notorious phenotypes, it
has been shown that a truncated CD133, which is not transported
to cell membrane, leads to human retinal degeneration [6].
Underlining this important observation, analysis of a generation of
CD133-deficient mice revealed that, while expressed very early
during retinal development, CD133 acted as a key regulator of
disk morphogenesis and that loss of CD133 caused photoreceptor
degeneration and blindness [7]. In addition, AC133, a glycosylat-
ed epitope of CD133 protein initially associated with embryonic
stem cells [8] and a variety of somatic stem cells, was extensively
described as a putative cancer stem cell marker in blood, brain,
colon, prostate, lung, breast, liver, and skin cancers [9,10]. Other
investigations revealed that CD133 is linked to cell metabolism as
a glucose responsive gene in myotubes [11], as well as providing
evidence for bioenergetic stress [12] and of non-exposure to high
oxygen tension in gliomas (Bourseau-Guilmain et al., submitted).
At the subcellular level, CD133 is preferentially localized in
plasma membrane protrusions and microvilli [13]. From there,
CD133 can bind to cholesterol [14] and interact with gangliosides
[15]. As membrane protrusions and microvilli enable extension of
the membrane surface in order to increase cell exposure to the
extracellular space, these observations provide important clues to
identifying the molecular role of CD133, notably by considering
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was found in membrane vesicles distinct from exosomes that were
released from epithelial cells during differentiation [16].
In parallel to these outside-in signals, cholesterol and sphingo-
lipids segregate in lipid raft membrane microdomains implicated
in inside-out signaling and endocytosis [17,18]. Considering the
tight relation between CD133 and cholesterol, plus its possible link
to sphingolipids and exposure to the extracellular space, we
hypothesized that CD133 is involved in endocytosis: a fundamen-
tal process by which extracellular compounds are internalized and
distributed to intracellular compartments.
In the present study, using the RNA-interference strategy and
undifferentiated human colon cancer Caco-2 cells that constitu-
tively over-expressed CD133/AC133, we provide for the first time
evidence for a role of CD133 in the intracellular accumulation of
extracellular compounds, notably exemplified by transferrin (Tf).
In addition to data that establish a role for CD133 in endocytosis,
we also demonstrate that CD133 itself is regulated by iron, thus
supporting the existence of a Tf-CD133-iron network. These new
observations are discussed in the light of the CD133 pattern of
expression and current knowledge in the field.
Materials and Methods
Cell culture
Undifferentiated human colon carcinoma Caco-2 cells (Amer-
ican type culture collection: HTB-37
TM) were cultured at 37uCi n
an atmosphere of 5% CO2 in Dulbecco’s Modified Eagle Medium
(DMEM; Lonza, Levallois-Perret, France) containing 4.5 g/L
glucose and L-glutamine. The medium was added with 10% of
fetal bovine serum (FBS; Lonza, Verviers, Belgium), 1% antibiotics
(10 units/mL penicillin, 10 mg/mL streptomycin, 25 mg/mL
amphotericin B; Sigma-Aldrich, Saint-Louis, USA, MO) and 1%
of non-essential amino acids (NEAA; Lonza, Verviers, Belgium).
When cells reached 80% confluence, they were dissociated in
0.5% porcine trypsin and 0.2 g/mL EDTA (Lonza, Verviers,
Belgium) before re-plating on uncoated plastic flasks at 15610
3
cells/cm
2. Half the medium was replaced by fresh medium every
two days.
siRNA knockdown of CD133
Caco-2 cells were plated in six-well plates with 2.3610
5 cells per
well in 2 mL of the aforementioned medium for 24 h. Medium
was removed and cells were transfected with 30 nM of RNA
oligonucleotide duplexes (Sigma-Aldrich) using the N-TER
reagent according to manufacturer’s instructions (Sigma-Aldrich).
N-TER/siRNA complexes were then incubated in Caco-2
medium for 48 h at 37uC in an atmosphere containing 5%
CO2. siRNA were then removed and replaced by fresh medium
for 24 h. A sequence scramble was used as negative control: 59-
GUCCGGAAUUACCAUGAGUdTdT-39. The sequence used to
perform targeted RNA interference inhibition of CD133 was 59-
CCCUUAAUGAUAUACCUGAdTdT-39.
AC133 immunolabeling
Caco-2 cells exposed to siRNA were collected and dissociated
using Versene (Lonza). Cells were incubated with 5 mg/mL
AC133 antibody (Miltenyi Biotech, Paris, France) or IgG1k
isotype control (BD-Biosciences, Le Pont-de-Claix, France) for 1 h
at 4uC in PBS containing 5% FBS and 0.02% sodium azide. Cells
were then washed three times in PBS containing 5% FBS and
0.02% sodium azide, and incubated for 30 minutes at 4uC with
FITC-conjugated goat anti-mouse IgG F(ab’)2 fragment polyclon-
al antibody (Dakocytomation, Trappes, France) at 20 mg/mL in
PBS containing 5% FBS and 0.02% sodium azide. Following three
more washes in PBS containing 5% FBS and 0.02% sodium azide,
cells were re-suspended in PBS containing 2% formaldehyde and
0.02% sodium azide.
Flow cytometry
A BD FACSCalibur
TM fluorescent-activated flow cytometer
and the BD CellQuest
TM software (BD-Biosciences) were used for
flow cytometry acquisition. Analysis was carried out using
WinMDI 2.9 software (Scripps Institute, La Jolla, CA, USA).
Synthesis of Nile red-labeled lipid nanocapsules (NR-LNC)
50 nm Nile red (NR)-labeled lipid nanocapsules (LNC) (NR-
LNC) that incorporated the fluorescent compound NR were
prepared as previously described [19] by using a phase inversion
process that follows the formation of an oil/water microemulsion
containing triglycerides (LabrafacH WL 1349, Gattefosse ´, Saint-
Priest, France), a non ionic hydrophilic surfactant (SolutolH HS 15,
Gmbh, Ludwigshafen, Germany) and lecithins (Lipoı ¨dH S75-3,
Gmbh). NR was dissolved in acetone at 1% (w/w), and the
resulting NR solution was incorporated in LabrafacH at 1:10 (w/
w). Thus, 846 mg SolutolH, 75 mg Lipoı ¨dH, 1029 mg LabrafacH
containing NR, 89 mg NaCl and 2975 mg water were mixed and
heated under magnetic stirring up to 85uC. Three cycles of
progressive heating and cooling in between 85uC and 60uC were
then realized. They were finally followed by an irreversible shock
induced by dilution with 12.5 mL of 0uC deionised water added
into the inversion phase zone. Size exclusion and high-pressure
liquid chromatography (HPLC) assays demonstrated a complete
encapsulation and retention of NR as previously observed [19].
LNC were analysed for their size distribution using a Malvern
ZetasizerH Nano Series DTS 1060 (Malvern Instruments S.A.,
Worcestershire, UK).
Internalization of transferrin (Tf), dextran (Dx), cholera
toxin subunit B (CTB) and lipid nanocapsules (LNC)
The medium of transfected cells was removed and replaced by
DMEM supplemented with 1% of serum-free N1 medium (Sigma
Aldrich) for 1 h. The three following compounds, Tf-Alexa 488 at
0.5 and 5 mg/mL (Invitrogen, Cergy Pontoise, France), Dx-FITC
at 0.5 and 5 mg/mL (Sigma Aldrich) and CTB-FITC at 1 and
10 mg/mL (Invitrogen), or instead, NR-LNC at 1/1000 dilution
from initial suspension thus corresponding to a 100 mg/mL
concentration, were then added to the medium for 1 h. Cells
were then dissociated using Versene (Lonza). To enable
determination of the fraction of labeled molecules or particles
that was effectively internalized within cells, extracellular fluores-
cence was quenched using 0.4% trypan blue (Sigma Aldrich). Cells
were then washed in PBS and re-suspended in PBS containing 2%
formaldehyde and 0.02% sodium azide. Internalization of
fluorescently labeled Tf, Dx, CTB and LNC was monitored by
flow cytometry.
Analysis of the release of Tf from Caco-2 cells after
internalization
Control and CD133-specific siRNA were used to generate
CD133
high and CD133
low transfected Caco-2 cells, respectively.
Cells were then incubated with Tf-Alexa 488 for 2 h at 37uC/5%
CO2 before the extracellular media was removed, washed and
replaced by fresh medium free from Tf-Alexa 488. After further
incubation at 37uC/5% CO2 for 1 h, 2 h and 3 h, the remaining
intracellular Tf-Alexa 488 fluorescence, representing the amount
of Tf-Alexa 488 that was not recycled to the extracellular
CD133 and Endocytosis
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as described above.
Cell treatment with chemical inhibitors of endocytosis
and cellular uptake of Tf
Previously identified chemical inhibitors of known endocytic
pathways were used as previously described [19,20,21]. Briefly,
transfected Caco-2 cells were pre-treated with inhibitors for 1 h at
37uC in N1 medium. Chlorpromazine (10 mg/mL; Sigma-Aldrich)
was used to inhibit clathrin-mediated transport [22], while filipin
(1 mg/L; Sigma-Aldrich) and dimethylamiloride (DMA, 10 mM;
Sigma-Aldrich) were used to inhibit caveolae-dependent endocy-
tosis [23] and macropinocytosis [24], respectively. Cholesterol
depletion was obtained by a 2 h pretreatment with methyl-b-
cyclodextrine (MbCD, 10 mM; Sigma-Aldrich) in the presence of
lovastatin (1 mg/mL; Sigma-Aldrich) [25,26]. Subsequently, cellu-
lar uptake of 5 mg/mL Tf-Alexa 488 was monitored by flow
cytometry analysis as described above. For cholesterol inhibition,
1 mg/mL lovastatin was also maintained in the medium during the
treatment with Tf-Alexa 488.
Analysis of Tf uptake by Caco-2 cells after treatment with
the AC133 antibody
Caco-2 cells were plated at 2.3610
5 in 24-well plates in 400 mL
of serum containing medium. After a 24 h initial incubation at
37uC/5% CO2 the initial medium was replaced by N1 serum free
medium before incubation with either 0, 5, or 10 mg/mL of the
AC133 antibody or of isotype control IgG1k. Tf-Alexa 488 was
then added at 5 mg/mL and incubated at 37uC/5% CO2 for 1 h
to study the impact of the immunoglobulin treatment on Tf-Alexa
488 uptake. Tf-Alexa 488 uptake was quantified by flow cytometry
as described above.
Antibody recognition of the Tf receptor at surface the
Caco-2 cell depending on the level of CD133 expression
Caco-2 cells exposed to CD133 or control siRNA were collected
and dissociated using Versene (Lonza). Cells were incubated with
5 mg/mL CD71 mouse monoclonal antibody that recognize the Tf
receptor (TfR or CD71 antigen) (clone M-A712, BD-Biosciences)
or with 5 mg/mL IgG2a, k isotype control (BD-Biosciences) to
proceed for immunolabeling and flow cytometry as described
above for AC133 cell surface recognition.
Immunocytochemisty combined with confocal laser
scanning microscopy for the identification of AC133,
CD71 and clathrin heavy chain within Caco-2 cells
Caco-2 cells were plated at 4610
3 cells per well in eight-well
Lab-Tek Chamber Slides (Nunc, Roskilde, Denmark) in 300 mL
DMEM containing 10% FCS for 24 h. They were then exposed to
CD133 or control siRNA as described above before to proceed to
immunocytochemistry. Cells were then washed with PBS and
fixed with 4% paraformaldehyde in PBS (pH 7.4) for 20 minutes
at 4uC. After washes in PBS, cells were exposed for 60 minutes at
room temperature to a blocking solution of PBS containing 4% of
bovine serum albumin (Sigma-Aldrich) and 10% of normal goat
serum (Sigma-Aldrich). Primary monoclonal antibodies against
CD133 (IgG1k, Miltenyi Biotech), TfR or CD71 (IgG2ak, BD-
Biosciences) or clathrin heavy chain (CHC) (IgG1, BD-Bioscienc-
es) were incubated at 5 mg/mL in PBS/BSA 4% for overnight at
4uC. Note that for CHC intracellular immunolabeling, TritonH X-
100 was added at 0.1% during the blocking procedure for cell
permeation. After washes, a secondary horse anti-mouse biotin-
conjugated antibody (Vector, Burlingame, CA) was applied at 1/
100 in PBS/BSA 4% for 1 h at room temperature. After
additional washes, Streptavidin Fluo Probe Alexa 488 (Interchim,
Montluc ¸on, France), diluted 1/700, was used. Cells were finally
washed and mounted under coverslip in fluorescent mounting
medium (Dakocytomation). Confocal microscope images were
obtained by using an Olympus Fluoview
TM FU 300 confocal laser
scanning microscopy imaging system (Paris, France).
Iron treatments
Caco-2 cells were plated in six-well plates with 2.3610
5 cells per
well in 2 mL for 24 h. Before iron treatment started, FBS
containing medium was replaced by serum free N1 medium for an
additional 24 h. Cells were then treated with various concentra-
tions (50–800 mM) of ferric nitrilotriacetic acid (Fe-NTA) for 72 h
at 37uC/5% CO2, as indicated. Fe-NTA (molar ratio 1:4) was
extemporaneously prepared as a 20-mM stock from NTA and
ferric chloride hexahydrate (Sigma-Aldrich). Cells were alterna-
tively treated with FeSO4 (Sigma-Aldrich), another iron donor
[27,28], at either 150 or 300 mM for 24 h.
Iron deprivation and treatment with hypoxia-mimetic
agents
Following a similar culture procedure as before iron treatment,
cells were instead treated for 24 h with an iron chelator, also
known as a hypoxia-mimetic agent, Desferrioxamine (DFO,
Sigma-Aldrich) at 100 and 150 mM [29,30]. Alternatively, they
were treated for 24 h with a hypoxia-mimetic agent that works
independently from iron deprivation, Cobalt dichloride (CoCl2,
Sigma-Aldrich) at 100 and 150 mM [31].
Database, bioinformatics
To search for putative iron responsive element (IRE) sequences
within the 39 and 59 untranslated region (UTR) of human CD133
mRNA, the sequences used in this study (among which Homo
sapiens prominin 1 transcript variant 2, NM_001145847.1) were
obtained from NCBI GenBank. All sequence alignments were
done using the ClustalW computer program from the EMBL
European Bioinformatics Institute (Heidelberg, Germany). The
SIREs (searching for IREs) web server (http://ccbg.imppc.org/
sires/) was also used for prediction of iron responsive elements in
RNA [32].
Statistical analysis
XLSTAT 2006 Version 2006.3 (Addinsoft Paris, France) was
used for data analysis. The statistical significance of each
experiment was determined by a Dunnett’s test. The tests were
considered as significant with p values ,0.05.
Results
Impact of specific siRNA-mediated knockdown of CD133
on the intracellular accumulation of Tf, Dx and CTB in
non-differentiated Caco-2 cells
To determine the potential influence of CD133 on the
intracellular accumulation of extracellular compounds, non-
differentiated human colon carcinoma Caco-2 cells, which
naturally express high levels of CD133, were used. Using either
siRNA that does not lead to transcriptional down-regulation
(control siRNA) or siRNA that does down regulate targeted
CD133 mRNA and protein expression (CD133 siRNA), two
situations were analyzed: Caco-2 cells expressing high levels of
CD133, and Caco-2 cells expressing low levels of CD133.
Figure 1A shows that treatment of Caco-2 cells with 30 nM of
CD133 and Endocytosis
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protein expression, analyzed by flow cytometry immunofluores-
cence (AC133 antibody) compared to the control siRNA. To
analyze Caco-2 cell pinocytic ability in the CD133
high and
CD133
low situations, the intracellular accumulation of exogenous
markers of pinocytic pathways was then monitored. Although
alternative internalization pathways have been described depend-
ing on cell types and differentiation status (for review see [33]), Tf-
Alexa 488, Dx-FITC and CTB-FITC were used as prototype
markers of receptor mediated endocytosis [34], fluid phase
endocytosis [24,35] and caveolae dependent endocytosis [23,36],
respectively. Flow cytometry measurement of intracellular fluo-
rescence after 1 h exposure of CD133
high-Caco-2 cells to either 0.5
or 5 mg/mL Dx-FITC, 1 or 10 mg/mL CTB-FITC and 0.5 or
5 mg/mL Tf-Alexa 488 enabled 100% uptake to be measured
compared to the basal geomean fluorescent intensity of vehicle
alone treated cells representing 0% uptake. Although CD133
knockdown had no impact on intracellular accumulation of Dx-
FITC (Figure 1B) or on CTB-FITC (Figure 1C), cellular uptake of
Tf-Alexa 488 was significantly amplified in CD133
low-Caco-2 cells
whatever the concentration tested (Figure 1D). These data thus
established for the first time that CD133 act as a modulator of
intracellular accumulation of exogenous compounds.
Effect of siRNA mediated knockdown of CD133 on Tf
exocytosis
In view of the fact that CD133 appeared to be an inhibitor of
cellular uptake of Tf while having no impact on Dx and CTB, we
further focused on the relation between CD133 expression and Tf
accumulation. The potential effect of siRNA mediated knockdown
of CD133 on Tf-Alexa 488 exocytosis was therefore investigated.
For this purpose, CD133
high and CD133
low non-differentiated
Caco-2 cells were incubated with Tf-Alexa 488 for 2 h at 37uC/
5% CO2 before the extracellular medium was removed, washed
and replaced by fresh medium free from Tf-Alexa 488. After
further incubation for 1, 2 and 3 h at 37uC/5% CO2 the amount
of Tf-Alexa 488 that was not recycled to the extracellular
compartment was measured by flow cytometry as described in
Materials and Methods. Data presented in Figure 2 established
that intracellular levels of Tf-Alexa 488 decreased with incubation
time. After 1 h of incubation more than 80% of the internalized
Tf-Alexa 488 remained within cells in both CD133
high and
CD133
low expressing cells while after a 3 h of incubation, 5469%
and 4364% of the internalized Tf-Alexa 488 remained within
CD133
high and CD133
low expressing cells, respectively. However
at all times studied, no significant difference was observed
depending on CD133 expression levels (Figure 2). These
Figure 1. Specific siRNA mediated knockdown of CD133 within non-differentiated Caco-2 cells led to an increase in Tf intracellular
accumulation but had no impact on Dx and CTB uptake. A) Immunofluorescence associated flow cytometric analysis of CD133 expression on
non-differentiated Caco-2 cells treated with 30 nM of control or CD133-specific siRNA. Results are expressed as a percentage of the control treatment,
representing the geomean fluorescence intensity levels obtained after AC133 immunostaining of cells treated with irrelevant siRNA (CD133
high Caco-
2 cells); note the effective down regulation of CD133 when CD133-specific siRNA (CD133
low Caco-2 cells) was used. B–D) Flow cytometric analysis of
intracellular uptake of Dx-FITC (B), CTB-FITC (C) and Tf-Alexa 488 (D) within CD133
high and CD133
low Caco-2 cells after 1 h of incubation at 37uC/
5%CO2. Results are expressed as percentage of control, thus representing the geomean fluorescence intensity levels obtained for cells treated with
vehicle alone. Data represented mean 6 s.e.m. obtained from three independent experiments. Dunnett’s test: **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025515.g001
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both CD133
high and CD133
low non-differentiated Caco-2 cells,
short term differences in intracellular Tf accumulation are due
essentially to the impact of CD133 on endocytosis mechanisms
rather than exocytosis.
Effect of chemical inhibitors of known endocytic
pathways on the uptake of Tf by non-differentiated
Caco-2 cells depending on the level of CD133 expression
underlined the importance of the clathrin pathway
Having established that the level of expression of CD133 had an
impact on Tf uptake within non-differentiated Caco-2 cells but did
not modulate Tf recycling, we then addressed the question whether
CD133 is involved in specific pinocytic pathways [33]. For this
purpose, uptake of Tf-Alexa 488 within CD133
high and CD133
low
expressing cells was monitored after treatment with previously
identified chemical inhibitors of known endocytic pathways.
Chlorpromazine was used to inhibit clathrin mediated transport
[22], filipin to inhibit caveolae dependent endocytosis [23] and
DMA to inhibit macropinocytosis [24]. Flow cytometry established
that pretreatment of control CD133
high Caco-2 cells with filipin,
chlorpromazine and DMA before exposure to 5 mg/mL Tf-Alexa
488, led to a 30%, 90% and non-significant reduction in Tf uptake,
respectively (Figure 3A). The major impact of chlorpromazine
combined with the slighter effect of filipin thus emphasized that Tf
accumulationwithinnon-differentiated Caco-2cellswasmainlydue
to clathrin-mediated transport [37]. The filipin effect could be
explained by the fact endocytosis of protopic substrates for receptor-
mediated endocytosis, such as LDL or Tf,which usuallyroute to the
intracellular compartment through the clathrin pathway, could
alternatively use the caveolae pathway [38,39]. Moreover, as
cholesterol has been shown to be involved in the formation of
clathrin coated endocytic vesicles [26], filipin, which sequestrates
cholesterol, may also have an indirect impact on clathrin
endocytosis. Interestingly, when considering CD133 knockdown
and CD133
low Caco-2 cells, very similar data were obtained with
filipin, chlorpromazine and DMA, leading to 18%, 85% and non-
significant reduction in Tf uptake, respectively (Figure 3A). Thus,
the quantitative effects of CD133 on Tf endocytosis appear to be
mainly related to the clathrin-dependent pathway. Surprisingly,
cholesterol depletion, achieved by using MbCD combined with
lovastatin [25,26], which has been said to affect clathrin
independent pathways and to some extent clathrin dependent
pathways [26,40,41], resulted in a major improvement in Tf-Alexa
488 accumulation within CD133
high Caco-2 cells (+49%,
Figure 3A). Interestingly, the impact of cholesterol depletion on
Tf-Alexa 488 uptake within CD133
low Caco-2 cells was less marked
(+21%, Figure 3A). These last data supported the hypothesis that
CD133 interaction with intracellular cholesterol also has an impact
on Tf endocytosis. To further corroborate a possible link between
CD133 and the clathrin-dependent endocytosis pathway, impact of
CD133 knockdown on the uptake of synthetic nanoparticles (LNC)
that were previously described to use the clathrin pathway on route
to the intracellular space of Caco-2 cells [21] was investigated.
Interestingly, as for fluorescent Tf, uptake of fluorescently tagged
LNC (NR-LNC) was significantly higher in CD133
low Caco-2 cells
(Control siRNA) as compared with CD133
high Caco-2 cells (CD133
siRNA) (Figure 3B).
Treatment of non-differentiated Caco-2 cells with the
AC133 antibody recognizing the extracellular domain of
CD133 resulted in a reduction in Tf uptake
Having established that CD133 expression quantitatively
affected Tf endocytosis, we then considered that a direct
interaction between the CD133 protein and the Tf endocytic
machinery would have been affected by extracellular ligand
binding to CD133. As extracellular ligand of CD133 had not yet
been identified and since monoclonal antibodies have already
been used as activating or as function blocking immunoglobulins,
for instance in interactions between integrins and extracellular
matrix [42], the AC133 antibody, which recognizes an extracel-
lular glycosylation associated epitope of CD133 [43], was then
tested as CD133 ligand on living Caco-2 cells. Interestingly, while
treatment of non-differentiated Caco-2 cells with an IgG1k isotype
control immunoglobulin had no effect on the intracellular
accumulation of Tf-Alexa 488 evaluated by flow cytometry
(Figure 4A), treatment with the AC133 antibody resulted in a
major reduction in Tf uptake of 3868% and 7561% at 5 and
10 mg/mL, respectively (Figure 4A). These data established that
AC133 can effectively exert functional effects on living cells here
ascribed to an interaction between CD133 itself and the Tf
endocytic machinery in non-differentiated Caco-2 cells.
siRNA knowkdown of CD133 resulted in a strong
improvement of the TfR accessibility from the
extracellular space
To further assess the accessibility to the TfR (or CD71) from the
extracellular compartment depending on the presence of CD133,
expression of the TfR/CD71 at the plasma membrane was
evaluated on CD133
low Caco-2 cells (Control siRNA) and
CD133
high Caco-2 cells (CD133 siRNA). Immunofluorescence
combined with flow cytometry analysis demonstrated a dramatic
improvement of CD71/TfR recognition by the corresponding
antibody when CD133 was concomitantly down regulated
through siRNA knockdown (from 11.74 to 85.94 arbitrary units,
p,0.001, Figure 4B). Immunocytochemistry combined with
Figure 2. Specific siRNA mediated knockdown of CD133 within
non-differentiated Caco-2 cells did not affect short-term Tf
exocytosis. CD133
high (control siRNA) and CD133
low (CD133 siRNA)
non-differentiated Caco-2 cells were exposed to Tf-Alexa 488 for 2 h at
37uC/5% CO2 before the extracellular medium was removed, washed
and replaced by fresh medium free from Tf-Alexa 488. Amounts of Tf-
Alexa 488 that were not recycled to the extracellular compartment were
measured by flow cytometric analysis after further cell incubation at
37uC/5% CO2 for 1 to 3 h. Data are expressed as a % of Tf-Alexa 488
initially internalized. They represent mean 6 s.e.m. obtained from three
independent experiments.
doi:10.1371/journal.pone.0025515.g002
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(Figure 4C). Combined with the direct short-term effect of the
AC133 antibody on the uptake of Tf, these data supported a direct
or indirect interaction of CD133 with CD71/TfR at the plasma
membrane. In contrast, although the clathrin pathway was found
to be the major endocytic process for Tf within Caco-2 cells, no
evident differences were detected by immunocytochemistry in the
pattern of expression of CHC (Figure 4C).
Relation between iron supplementation or deprivation
and AC133/CD133 expression
Although Tf-independent iron transport can occur in mamma-
lian cells [44], the majority of extracellular iron is bound to Tf [45]
and uptake of iron occurs from iron loaded Tf through TfR
dependent endocytosis [33]. Interestingly, most of the proteins
involved in iron metabolism are regulated by iron itself notably
through iron regulatory proteins (IRP-1, IRP-2) that, in iron
starved cells, bind to cis-acting elements called iron responsive
elements (IREs) located in the 59 or 39UTR of transcripts
[46,47,48]. Thus, binding of IRPs to IREs located in the
59UTR of targeted messengers leads to inhibition of translation,
as exemplified by ferritin, which is up regulated in response to high
iron concentrations [49]. In contrast, recognition of IREs located
in the 39UTR of transcripts lead to their stabilization, as
exemplified by Tf, which is down regulated in response to high
iron concentrations [50]. Since the present work established that
Figure 3. Implication of CD133 in endocytosis mainly involved the clathrin pathway. A) Consequences of CD133-specific siRNA
knockdown for the effectiveness of chemical modulators of known endocytic pathways in modulating Tf uptake by non-differentiated Caco-2 cells.
After treatment with either vehicle alone (control), filipin, chlorpromazine, DMA or MbCD added with lovastatin (MbCD), CD133
high (control siRNA)
and CD133
low (CD133 siRNA) non-differentiated Caco-2 cells were exposed to 5 mg/mL Tf-Alexa 488. Cellular internalization of Tf-Alexa 488 was then
monitored by flow cytometry. Results are expressed as a % of Tf-Alexa 488 amounts that were internalized in the vehicle treated control. Note the
absence of effect of CD133-siRNA knockdown on the major inhibition of Tf-uptake caused by chlorpromazine. Note also the reduced up regulatory
effect of cholesterol extraction in the CD133 low situation (MbCD). Data represented mean 6 s.e.m. of a triplicate obtained from one representative
experiment that was reproduced twice. Comparisons with control: Dunnett’s test, *p,0.05, **p,0.01, ***p,0.001; comparison between control
siRNA and CD133 siRNA: Dunnett’s test: p,0.05. B) Specific siRNA mediated knockdown of CD133 within non-differentiated Caco-2 cells led to an
increase in LNC intracellular accumulation. Flow cytometric analysis of intracellular uptake of NR-LNC within CD133
high (Control siRNA) and CD133
low
(CD133 siRNA) Caco-2 cells after 1 h of incubation at 37uC/5%CO2. Results are expressed as percentage of control, thus representing the geomean
fluorescence intensity levels obtained for cells treated with vehicle alone. Data represented mean 6 s.e.m. obtained from three independent
experiments. Dunnett’s test: **p,0.01.
doi:10.1371/journal.pone.0025515.g003
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we further addressed the question whether AC133/CD133 was in
turn regulated by iron. For this reason, non-differentiated Caco-2
cells, previously placed in serum free medium, were treated with
extemporaneously prepared Fe-NTA (1:4) for 72 h at 37uC/5%
CO2 as described by others [44,51,52], thus allowing cells to
improve their iron contents. The impact of Fe-NTA treatment on
CD133/AC133 expression was then assessed by flow cytometry
(Figure 5A–C). As exposure to extracellular iron has previously
been shown to be toxic for cells [53], we checked that Fe-NTA
concentrations ranging from 50 to 800 mM had no impact on cell
shape and attachment (data not shown) or on cell death
(Figure 5A). Interestingly, while low concentrations of Fe-NTA
did not alter CD133/AC133 expression, 200 to 800 mM Fe-NTA
induced dose dependent down regulation of cancer stem cell
marker expression (Figure 5B–C). To confirm that iron supple-
mentation regulated CD133/AC133 expression, Caco-2 cells were
treated with FeSO4, another iron donor [27,28]. As shown on
Figure 5D, FeSO4 at 300 mM lead to a down regulation of
CD133/AC133 expression, while having no effect at 150 mM. To
further understand the modality of regulation of CD133/AC133
expression by iron, iron chelation with DFO was also investigated.
Interestingly, DFO treatment significantly reduced AC133
expression in Caco-2 cells in a dose dependent manner at 100
and 150 mM (Figure 5E). As iron supplementation expectedly had
opposite effect as iron deprivation on intracellular iron content,
the reduction of AC133 expression in both situations suggests the
possibility that supplementation and deprivation may work on
distinct pathways. As such, DFO is also known as a hypoxia-
mimetic agent, which by inhibiting the activity of prolyl
hydroxylases stabilizes the HIF-1a transcription factor [29,30].
To further cope with the hypothesis that DFO-induced hypoxia
Figure 4. Recognition of CD133 and modulation of its expression interfere with Tf uptake and TfR accessibility in Caco-2 cells.
A) AC133 antibody treatment inhibited Tf uptake. Constitutively CD133-expressing undifferentiated Caco-2 cells were exposed to Tf-Alexa 488 for 1 h
at 37uC/5%CO2 in the presence of 5 or 10 mg/ml of AC133 or IgG1k immunoglobulin control. Tf-Alexa 488 that was effectively internalized within cells
was then monitored by flow cytometry. Results are expressed as a % of Tf-Alexa 488 amounts that were internalized in the untreated control. Data
represented mean 6 s.e.m. from a triplicate obtained from one representative experiment. Dunnett’s test: *p,0.05, ***p,0.001. B) Flow cytometric
analysis of the expression of TfR (CD71) at the surface of CD133
high (Control siRNA) and CD133
low (CD133 siRNA) Caco-2 cells. Data represented mean
6 s.e.m. obtained from three independent experiments. IgG2ak immunoglobulins were used as negative control immunostaining. Dunnett’s test:
***p,0.001. C) Analysis of the expression of AC133, TfR/CD71 and CHC within Caco-2 cells by immunocytochemistry combined with confocal laser
scanning microscopy. Note the increase of CD71 expression while AC133 was depleted from the Control siRNA to the CD133 siRNA situation. Bar:
50 mm.
doi:10.1371/journal.pone.0025515.g004
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CoCl2 [31], a hypoxia-mimetic agent that stabilize HIF-1a and
works independently from iron deprivation, was investigated.
Figure 5F established that, similarly to DFO, CoCl2 at 100 and
150 mM strongly inhibited the expression of AC133/CD133
within Caco-2 cells. This observation emphasized that control of
AC133/CD133 expression by iron in Caco-2 cells may in parallel
to mRNA stabilization, also involved transcriptional regulation
notably through HIF-1a.
To get more information on the direct or indirect effect of iron
on AC133/CD133 expression, a search for putative IRE-like stem
loops within the 59UTR and 39UTR of human CD133 mRNA
was carried out using computer based sequence alignments as
described in Materials and Methods. Although previously
published IRE sequences [32,47,48,54,55,56,57,58] were not
recognized, and the SIREs Web research [32] failed to detect
any classical stem loop sequence within the 59UTR and 39UTR of
human CD133 mRNA, a hairpin loop presenting the non-
canonical CAGAGU sequence as observed in the first IRE
identified in the human TfR mRNA was identified in the 39UTR.
This selected sequence, which still requires investigation, is
presented among validated IREs in Figure 6.
Discussion
Our results provide evidence for an important role of the 5-
domain trans-membrane molecule CD133 in the regulation of
cellular cross-talk with the extracellular microenvironment,
revealed firstly by inhibition of Tf endocytosis in non-differentiated
Caco-2 cells, secondly by the ability of the CD133-specific AC133
antibody to also inhibit Tf endocytosis and thirdly by the negative
regulation of the TfR accessibility. Since Tf is the main iron
carrier entry to the mammalian cell, the identification of a role of
CD133 in endocytosis must be related to the regulation of CD133
Figure 5. Iron supplementation down regulated AC133/CD133 expression in Caco-2 cells in a dose-dependent fashion. Combined
immunofluorescence and flow cytometry was used to assess the impact of Fe-NTA treatment on AC133/CD133 expression in Caco-2 cells. A) Forward
scatter (FSC, approximate cell size) and side scatter (SSC, cell complexity or granularity) profiles of vehicle only treated cells (control) versus Fe-NTA
(800 mM) treated cells. B) Cell number distribution versus FITC-fluorescence (arbitrary units) in control and Fe-NTA (800 mM) treatments after IgG1
control or AC133 immunostaining. Dose-response histograms representing AC133/CD133 expression as a function of Fe-NTA (C), FeSO4 (D), DFO (E)
or CoCl2 (F) treatments at different concentrations as indicated. GFI: geomean fluorescence intensity. Data represent mean 6 s.e.m. of a triplicate
obtained from one representative experiment. Dunnett’s test: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025515.g005
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cell metabolism.
CD133 as an endocytosis modulator
The unique localization of the cholesterol binding protein
CD133 in plasma membrane protrusions and microvilli, as well as
in association with specific lipid raft microdomains that are
sensitive to Triton X100 but resistant to Lubrol WX supported the
hypothesis that CD133 has a significant function in plasma
membrane organization [14,59,60]. The role of CD133 was
suggested by the generation of apical membrane protrusions from
epithelial cells and notably in the release of extracellular
membrane particles, which themselves carry CD133 [16,61,62].
By further establishing, to our knowledge for the first time, a role
for CD133 in endocytosis, importantly the present study extends
the functionality of CD133 at the plasma membrane interface.
Thus, the quantitative effects of CD133 on Tf endocytosis, as well
as on LNC, can be mainly ascribed to the clathrin pathway, which
is the main Tf-internalization pathway within Caco-2 cells [33].
This assertion was also corroborated by the absence of effect of
CD133 knockdown on the uptake of Dx and CTB that are usually
internalized through fluid phase and caveolae dependent endocy-
tosis, respectively [33]. Hence, CD133-dependent up regulation of
Tf uptake after cholesterol extraction (MbCD treatment) support-
ed the hypothesis that CD133, at least partially, inhibits Tf
endocytosis via a cholesterol dependent mechanism. Accordingly,
cholesterol extraction either up regulates Tf uptake via an
unknown compensatory mechanism or alternatively, reduces
constitutive extracellular Tf recycling. It has previously been
established that acute cholesterol extraction can increase the
number of TfR on the cell surface [41,63], thus explaining
relatively higher Tf entry to the cell, notably in the inhibitory
CD133
high situation. Also, absence of a differential effect of filipin
treatment depending on CD133 expression emphasized the fact
that cholesterol extraction (MbCD treatment) has different effects
than cholesterol sequestration (filipin treatment) on pinocytic
pathways. However, since the influence of CD133 on Tf
endocytosis involved the clathrin pathway and cellular cholesterol,
an interaction of the CD133 molecule with the TfR, whatever the
endocytic pathway involved, cannot be excluded. Hence, the effect
of the AC133 antibody on Tf endocytosis may either support steric
shielding affecting the binding of Tf to its receptor or, instead,
signaling through the CD133 molecule that affects Tf-TfR uptake.
The dramatic up regulation of the TfR expression at the plasma
membrane of Caco-2 cells when CD133 was concomitantly down
regulated validated such interaction between CD133 and the TfR.
Among signaling pathways, a previous work demonstrated CD133
phosphorylation of the cytoplasmic domain by Src and Fyn
tyrosine kinases [5]. Whether the presence of the AC133 epitope
in the CD133 extracellular domain and binding to an as yet
unidentified ligand influences CD133 phosphorylation and
resulting signaling remains a major question. CD133 may thus
modulate Tf uptake through direct inhibitory effects on TfR or on
the structure of TfR microdomains. Moreover, alteration of
ongoing mechanisms that promote Tf-TfR turnover may be
involved: for instance, insulin stimulated redistribution of TfR to
the plasma membrane [64], hemochromatosis protein co-traf-
ficked with the TfR to the cell surface [65] and PI3kinase-mTOR
regulated the number of TfR per endocytic vesicle [66].
Alternatively, as CD133 is a glycosylated molecule, glycosylation
could be important for the regulation of Tf binding to the cell
surface and likely in iron metabolism [67].
CD133 as an integrator of cell metabolism
Supporting the aerobic glycolysis of cancer cells first reported by
Otto Warburg in the 1950s [68], it was recently established that
CD133 expression is associated with high cellular glucose
metabolism: CD133 was found to be a glucose responsive gene
in L6 myotubes [11] and CD133 expression to be concomitant to
high glucose cellular uptake in U251 glioma cells [12]. Since co-
localization of glucose transporters with the TfR in intracellular
vesicles has previously been observed [69,70,71], whether CD133
can regulate iron uptake together with glucose transport by
Figure 6. Schematic representation of known IREs and nearest
related stem loop sequence located in the 39UTR of the CD133
mRNA (NCBI GenBank accession number NM_001145847.1,
nucleotide sequence: from +3544 to +3574). Note the perfect
match between the 59-ACAGAGUU-39 loop sequence of the CD133
mRNA and the one present in the TfR1 39IRE. Note also the high
discrepancy between hairpin structures, notably with the presence of
secondary loops (dashed line) in the APP 59IRE. A secondary loop is also
present in the CD133 hairpin selected here. CDC14A: dual specificity
protein tyrosine phosphatase. DMT1: divalent metal transporter 1.
75 kDa Fe-S: NADH dehydrogenase (ubiquinone) Fe-S protein 1. APP:
Alzheimer amyloid precursor protein. Ft-H: ferritin heavy chain.
doi:10.1371/journal.pone.0025515.g006
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combined sequestration of TfR and glucose transporter at the
plasma membrane would be expected to result in low iron levels
combined with high glucose intracellular levels. As iron-sulfur
cluster assembly [72] is an important process for mitochondria
activity, inhibition of a respiratory phenotype may well fit with the
appearance of a glycolytic one [73]. Having established here that
CD133 knockdown up regulated holo-Tf uptake and that iron
supplementation and deprivation down regulated CD133 expres-
sion, a role for CD133 as an integrator of iron metabolism, with
CD133 and TfR being jointly modulated [48], is suspected. In line
with this hypothesis, direct effects on putative IREs may be
involved in the regulation of CD133 expression by iron.
Considering homology but also a degree of variability among
IREs, as for instance between TfR 39IRE [48] and APP 59IRE
[58] (Figure 6), the stem loop sequence we selected for possible
CD133 39IRE (Figure 6) remained to be either validated or
rejected. Alternatively, indirect regulation of CD133 expression
may be implicated. As an illustration of the latter, also supported
by our experiments using DFO and CoCl2, oxygen sensing [74,75]
and mTOR [76] have been shown to regulate CD133 expression
via activation of the HIF-1a transcription factor. Since iron
treatment can in turn modulate HIF-1a activity [77,78,79], iron
induced destabilization of HIF-1a may also explain down
regulation of CD133 expression in non-hypoxic conditions [80].
Consequences for cancer cell behavior and for
detoxification status
It has previously been established that the AC133 epitope is lost
during Caco-2 cell differentiation but not the CD133 protein [60].
In addition, differentiation of Caco-2 cells up regulates genes
implicated in iron transport and metabolism, including ferropor-
tin, Tf and TfR [81]. Thus, whether causative or not, improved
iron metabolism appears to be correlated with the differentiation
status of Caco-2 cells. Whether iron regulation of AC133
expression is a basic signal for differentiation or/and for cancer
cell recruitment to a secondary phenotype is of pivotal interest.
Also, several extrinsic signaling molecules have already been linked
to the loss of expression of AC133 associated with differentiation,
notably in brain tumor stem cells with BMP-4 [82], retinoic acid
[83] or oxygen [74,75]. Our identification of a role for CD133/
AC133 in inhibiting endocytosis points to another consequence of
cellular cross-talk between cancer cells and their microenviron-
ment, or of cancer stem cells and the stem cell niche, that is a finest
control of extrinsic signals. Indeed, corruption of the niche as well
as the exclusion of toxic metabolites and xenobiotics appears to be
an important mechanism to define the status of cancer stem cells,
with the occurrence of side population cells that express specific
efflux transporters [84]. Hence, a fine control of iron accumulation
might prevent the generation of deleterious reactive oxygen species
via iron catalyzed Fenton chemistry [46], with a possibly impact
on iron-induced carcinogenesis [85] and on degenerative diseases
[86,87]. Since a major phenotype for CD133 loss was disk
dysmorphogenesis and photoreceptor degeneration [7] and since
iron toxicity can trigger retinal degeneration [88], the present
work emphasized the need for further exploration of the newly
revealed CD133-Tf-iron network.
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